(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.48%) $83.45
(-1.16%) $1.619
(-0.05%) $2 346.10
(-0.20%) $27.48
(0.29%) $924.80
(0.29%) $0.934
(0.62%) $11.02
(0.08%) $0.800
(0.00%) $92.17
Live Chart Being Loaded With Signals
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and Hong Kong...
Stats | |
---|---|
Šios dienos apimtis | 9.96M |
Vidutinė apimtis | 9.12M |
Rinkos kapitalizacija | 31.66B |
EPS | HKD0 ( 2024-03-27 ) |
Last Dividend | HKD0.160 ( 2023-06-05 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 7.64 |
ATR14 | HKD0.00600 (0.12%) |
Tūris Koreliacija
China Resources Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
China Resources Koreliacija - Valiuta/Žaliavos
China Resources Finansinės ataskaitos
Annual | 2023 |
Pajamos: | HKD270.40B |
Bruto pelnas: | HKD42.36B (15.67 %) |
EPS: | HKD0.680 |
FY | 2023 |
Pajamos: | HKD270.40B |
Bruto pelnas: | HKD42.36B (15.67 %) |
EPS: | HKD0.680 |
FY | 2022 |
Pajamos: | HKD254.11B |
Bruto pelnas: | HKD39.13B (15.40 %) |
EPS: | HKD0.660 |
FY | 2021 |
Pajamos: | HKD236.81B |
Bruto pelnas: | HKD35.38B (14.94 %) |
EPS: | HKD0.600 |
Financial Reports:
No articles found.
China Resources Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.160 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0900 | 2017-05-24 |
Last Dividend | HKD0.160 | 2023-06-05 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 8 | -- |
Total Paid Out | HKD0.980 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.49 | -- |
Div. Sustainability Score | 8.46 | |
Div.Growth Potential Score | 4.24 | |
Div. Directional Score | 6.35 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9889.HK | Ex Dividend Junior | 2023-05-30 | Annually | 0 | 0.00% | |
2148.HK | Ex Dividend Junior | 2023-10-03 | Sporadic | 0 | 0.00% | |
1138.HK | Ex Dividend Junior | 2023-07-18 | Sporadic | 0 | 0.00% | |
0222.HK | Ex Dividend Junior | 2023-06-26 | Annually | 0 | 0.00% | |
3838.HK | Ex Dividend Junior | 2023-06-12 | Annually | 0 | 0.00% | |
1723.HK | Ex Dividend Junior | 2023-09-04 | Sporadic | 0 | 0.00% | |
0759.HK | Ex Dividend Junior | 2023-10-09 | Sporadic | 0 | 0.00% | |
2318.HK | Ex Dividend Knight | 2023-09-11 | Semi-Annually | 0 | 0.00% | |
1286.HK | Ex Dividend Knight | 2023-08-21 | Semi-Annually | 0 | 0.00% | |
0347.HK | No Dividend Player | 2023-06-01 | Sporadic | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0158 | 1.500 | 9.68 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0156 | 1.200 | 9.48 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0800 | 1.500 | -0.222 | -0.334 | [0.1 - 1] |
payoutRatioTTM | 0.245 | -1.000 | 7.55 | -7.55 | [0 - 1] |
currentRatioTTM | 1.330 | 0.800 | 8.35 | 6.68 | [1 - 3] |
quickRatioTTM | 0.799 | 0.800 | -0.00494 | -0.00395 | [0.8 - 2.5] |
cashRatioTTM | 0.236 | 1.500 | 9.80 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.313 | -1.500 | 4.79 | -7.19 | [0 - 0.6] |
interestCoverageTTM | 4.41 | 1.000 | 9.48 | 9.48 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.555 | 2.00 | 9.48 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.054 | 2.00 | 9.47 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 1.678 | -1.500 | 3.29 | -4.93 | [0 - 2.5] |
grossProfitMarginTTM | 0.157 | 1.000 | -0.722 | -0.722 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0431 | 1.000 | -1.139 | -1.139 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.127 | 1.000 | -0.407 | -0.407 | [0.2 - 2] |
assetTurnoverTTM | 0.992 | 0.800 | 6.72 | 5.38 | [0.5 - 2] |
Total Score | 8.46 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 8.22 | 1.000 | 9.27 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0800 | 2.50 | -0.143 | -0.334 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.054 | 2.00 | 9.65 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.17 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.555 | 2.00 | 9.48 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.245 | 1.500 | 7.55 | -7.55 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0399 | 1.000 | -1.502 | 0 | [0.1 - 0.5] |
Total Score | 4.24 |
China Resources
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and Hong Kong. The company operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. It offers a range of chemical drugs, Chinese medicines, and biopharmaceutical drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular, alimentary tract, metabolism and endocrine, respiratory, orthopedics, oncology, medical nutrition, gastroenterology, pediatrics, genitourinary system, cough and cold, anti-infection, dermatology, infusion solutions, etc. The company also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it is involved in property holding activities. As of December 31, 2021, the company operated 801 retail pharmacies under the CR Care and Teck Soon Hong brands. It distributes its products to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.